Arrowstreet Capital, Limited Partnership Bellus Health Inc. Transaction History

Arrowstreet Capital, Limited Partnership

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$3.03 - $4.58 $1.49 Million - $2.26 Million	-492,798 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$2.27 - $3.3 $397,472 - $577,823	175,098 Added 55.11%	492,798 $1.51 Million
Q3 2020 Nov 12, 2020	BUY	$2.14 - $12.02 $679,878 - $3.82 Million	317,700 New	317,700 $721,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.